Drug Trial Radar · NCT06487559
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Sep 11, 2024
Primary completion
Sep 18, 2026
Study completion Sep 18, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to assess adverse events and how livmoniplimab in combination with budigalimab moves through the body in adult Chinese participants with Locally Advanced or metastatic Child-Pugh A Hepatocellular Carcinoma (HCC). Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. Stage 1 is a safety run-in. There are 2 treatment arms in stage 1 and participants will receive escalating doses of Livmoniplimab in combination with budigalimab (fixed dose). Stage 2 is dose expansion. There are 2 treatment arms in stage 2 and participants will receive Livmoniplimab in combination with budigalimab in multiple doses. Approximately 20 adult participants will be enrolled in the study across 15 sites in China. In part 1 (dose escalation), participants will be intravenously infused with escalating doses of livmoniplimab in combination with budigalimab every 3 weeks. In part 2 (dose expansion), participants will be intravenously infused with livmoniplimab in combination with budigalimab in multiple doses every 3 weeks. The estimated duration of the study is up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
LivmoniplimabDrug
Intravenous infusion
BudigalimabDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AE)Time frame: Up to Approximately 2 Years
- Number of Participants with Dose-Limiting Toxicities (DLT)Time frame: Up to Approximately 2 Years
- Maximum Plasma Concentration (Cmax) of Livmoniplimab and BudigalimabTime frame: Up to Approximately 2 Years
- Area Under the Serum Concentration Versus Time Curve (AUC) of Livmoniplimab and BudigalimabTime frame: Up to Approximately 2 Years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928
Beijing, Beijing Municipality, China
Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center /ID# 262092
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University /ID# 262091
Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital /Id# 262070
Harbin, Heilongjiang, China
Henan Cancer Hospital /ID# 262098
Zhengzhou, Henan, China
Hubei Cancer Hospital /ID# 262030
Wuhan, Hubei, China
The Second Affiliated Hospital of Nanchang University /ID# 262085
Nanchang, Jiangxi, China
Liaoning Cancer Hospital & Institute /ID# 268023
Shenyang, Liaoning, China
Zhongshan Hospital Fudan University /ID# 262135
Shanghai, Shanghai Municipality, China
Zhejiang Cancer hospital /ID# 262046
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.